UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 440

Sortiert nach

Pathways and mechanisms of venetoclax resistance

Leukemia & lymphoma, 2017-09, Vol.58 (9), p.2026-2039

2017

Volltextzugriff (PDF)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Blood cancer journal (New York), 2021-04, Vol.11 (4), p.79-12, Article 79

2021

Volltextzugriff (PDF)

Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies

Molecular and cellular biochemistry, 2021-01, Vol.476 (1), p.417-423

2021

Volltextzugriff (PDF)

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

Clinical cancer research, 2015-04, Vol.21 (7), p.1537-1542

2015

Volltextzugriff (PDF)

Correction to: Activation of ATM kinase by ROS generated during ionophore‑induced mitophagy in human T and B cell malignancies

Molecular and cellular biochemistry, 2021-07, Vol.476 (7), p.2887-2887

2021

Volltextzugriff (PDF)

Ibrutinib and Venetoclax for First-Line Treatment of CLL

The New England journal of medicine, 2019-05, Vol.380 (22), p.2095-2103

2019

Volltextzugriff (PDF)

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

Clinical cancer research, 2017-07, Vol.23 (14), p.3734-3743

2017

Volltextzugriff (PDF)

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

Clinical cancer research, 2014-04, Vol.20 (7), p.1735-1740

2014

Volltextzugriff (PDF)

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Blood, 2012-02, Vol.119 (5), p.1182-1189

2012

Volltextzugriff (PDF)

ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage

Therapeutic delivery, 2012-07, Vol.3 (7), p.823-833

2012

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

Expert opinion on drug metabolism & toxicology, 2016-11, Vol.12 (11), p.1381-1392

2016

Volltextzugriff (PDF)

A Conference of New Ideas in Cancer-Challenging Dogmas

Cancer research, 2017-01, Vol.77 (2), p.234-237

2017

Volltextzugriff (PDF)

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia

Molecular cancer research, 2017-12, Vol.15 (12), p.1692-1703

2017

Volltextzugriff (PDF)

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

Blood, 2011-07, Vol.118 (3), p.693-702

2011

Volltextzugriff (PDF)

Targeting MCL-1 protein to treat cancer: opportunities and challenges

Frontiers in oncology, 2023-07, Vol.13, p.1226289-1226289

2023

Volltextzugriff (PDF)

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

Blood, 2009-11, Vol.114 (19), p.4150-4157

2009

Volltextzugriff (PDF)

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Blood cancer journal (New York), 2022-05, Vol.12 (5), p.80-80, Article 80

2022

Volltextzugriff (PDF)

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance

Blood, 2009-01, Vol.113 (1), p.149-153

2009

Volltextzugriff (PDF)

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Haematologica (Roma), 2022-01, Vol.107 (1), p.292

2022

Volltextzugriff (PDF)

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Blood, 2009-11, Vol.114 (20), p.4441-4450

2009

Volltextzugriff (PDF)

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Blood, 2008-09, Vol.112 (5), p.1971-1980

2008

Volltextzugriff (PDF)

Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies

Seminars in oncology, 2002-08, Vol.29 (4 Suppl 13), p.4-11, Article asonc02904n0004

Gandhi, Varsha

2002

Volltextzugriff (PDF)

Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma

Haematologica (Roma), 2021-02, Vol.106 (2), p.495

2021

Volltextzugriff (PDF)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

Journal of hematology and oncology, 2021-04, Vol.14 (1), p.70-16, Article 70

2021

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(400)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Englisch
(440)
Japanisch
(49)

Erscheinungsjahr

n.n

Thema

Science & Technology
(250)
Life Sciences & Biomedicine
(243)
Humans
(231)
Oncology
(147)
Biological And Medical Sciences
(103)
Medical Sciences
(98)
Hematology
(95)
Pharmacology. Drug Treatments
(69)
Antineoplastic Agents
(66)
Female
(58)
Male
(56)
Adult
(50)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(50)
Middle Aged
(49)
Aged
(47)
Animals
(47)
Apoptosis - Drug Effects
(47)
Antineoplastic Agents - Pharmacology
(46)
Cell Line, Tumor
(43)
Hematologic And Hematopoietic Diseases
(41)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(84)
Cancer Research
(51)
Leukemia & Lymphoma
(31)
Clinical Cancer Research
(22)
Journal Of Clinical Oncology
(16)
Leukemia & Lymphoma/leukemia And Lymphoma
(16)
Clinical Lymphoma, Myeloma And Leukemia
(14)
Cancer
(10)
Seminars In Oncology
(9)
Molecular Cancer Therapeutics
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pathways and mechanisms of venetoclax resistance

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

Correction to: Activation of ATM kinase by ROS generated during ionophore‑induced mitophagy in human T and B cell malignancies

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

A Conference of New Ideas in Cancer-Challenging Dogmas

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

Targeting MCL-1 protein to treat cancer: opportunities and challenges

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies

Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

Suchergebnisse filtern